^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
...it is recommended that patients with TP53 deletion/mutation are treated with novel inhibitors (ibrutinib; idelalisib and rituximab) in front-line and relapse settings.
DOI:
10.1093/annonc/mdv303
Source:
Title:
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Excerpt:
The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high‐risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080‐0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91%...study showed improved efficacy of single‐agent ibrutinib over ofatumumab in patients with relapsed/refractory CLL/SLL...
DOI:
10.1002/ajh.25638
Trial ID:
Source:
Title:
therapy with ibrutinib for patients with Chronic lymphocytic leukemia with subclonal TP53 aberrations terapia con Ibrutinib per pazienti affetti da leucemia linfatica cronica che presentano alterazioni subclonali di TP53
Excerpt:
......
Trial ID:
Source:
Title:
Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
Excerpt:
34 patients who had CLL with TP53 alterations were treated with ibrutinib as first-line therapy...As the best response, 30% had a complete response to treatment...At 6 years, the estimated percentage of patients with progression-free survival and overall survival was 61% and 79%, respectively...The data that are summarized here underscore the longer durability of response with ibrutinib than with chemoimmunotherapy
DOI:
10.1056/NEJMc2005943
Trial ID:
